Analysis of Minimally Invasive Robotic-Assisted CABG Procedures Utilizing Intraoperative ICGA and Transit Time Flowmeter Testing

Heart surgery has long been a trade-off between fixing a blocked artery and the trauma required to reach it. For decades, the standard approach involved opening the chest completely, a procedure that is highly effective but leaves a significant recovery burden. In recent years, surgeons have developed a way to bypass these blockages using tiny incisions and robotic arms, a technique that spares the breastbone and allows patients to heal much faster. However, the success of any bypass depends entirely on the new bridge of tissue—the graft—staying open and carrying blood effectively to the heart muscle. If that bridge is kinked or narrowed, the surgery fails, and the patient remains at risk. To ensure the bridge is solid, surgeons have traditionally relied on ultrasound tools that measure how fast blood moves, but these tools can sometimes give confusing signals. A newer method uses a special dye that glows under infrared light, allowing the surgeon to see the blood flow in real time, almost like turning on a flashlight in a dark room. The question facing the medical community is whether using both of these tools together, rather than just one, provides a clearer picture of the surgery's success and leads to better outcomes for the patient.

A team of researchers at Reading Hospital, led by a single surgeon, set out to test this combined approach in a series of robotic heart bypass operations. They focused on 78 adult patients who underwent a specific type of minimally invasive procedure where a robotic arm was used to connect a healthy artery from the chest wall to a blocked artery on the surface of the heart. Unlike traditional surgeries that might involve multiple vessels, these patients received a single, focused bypass. During the operation, once the connection was made, the surgical team employed two distinct methods to check their work. First, they used a flow meter that clamped around the new vessel to measure the volume of blood passing through it and the rhythm of that flow. Second, they injected a safe, non-toxic dye called indocyanine green into the patient's bloodstream. As the dye traveled through the new graft, a camera on the robotic system captured a glowing image, showing exactly where the blood was going and whether any part of the vessel was blocked or twisted.

The results of this combined strategy were revealing. In about one out of every ten cases, the initial measurements suggested something was wrong with the graft. The flow meter showed the blood was moving too slowly or pulsing irregularly, and the glowing images confirmed that the vessel was kinked or not fully open. Because the team had these two tools working in tandem, they were able to identify these problems immediately while the patient was still on the operating table. In these eight instances, the surgeon went back in and adjusted the graft, fixing the kink or narrowing until the measurements improved. This proactive correction meant that the surgeons did not have to wait until after the surgery to discover a problem, nor did they have to rely on guesswork. Once the chest was closed, the patients went home, and the researchers tracked their recovery over the next month.

The data showed that the patients who underwent this procedure recovered well. The average time spent in the hospital was just under six days, and the rate of serious complications was remarkably low. There were no deaths, no strokes, and no heart attacks related to the surgery within the first thirty days. Perhaps most notably, the heart's pumping strength, known as the ejection fraction, improved significantly. Before the surgery, the average heart pumped with about 52 percent efficiency. Thirty days later, that number had risen to nearly 57 percent. While the researchers noted that many factors contribute to heart recovery and that a causal relationship between the graft assessment and this improvement cannot be definitively established from this study design, the fact that the grafts were verified and corrected in real time suggests that ensuring the blood flow was perfect from the start may have played a role in helping the heart muscle regain its strength.

The study also looked at the financial side of using these advanced tools. The robotic equipment and the dye used for the glowing images added specific costs to each surgery, but the researchers found that the overall expense was manageable for a community hospital. The flow meter, which provides the numerical data, is a one-time purchase for the hospital, while the dye is a small, recurring cost per patient. By catching and fixing problems before the patient left the operating room, the team likely avoided the much higher costs associated with returning to surgery or dealing with long-term heart failure. The findings suggest that while the upfront investment in technology is real, the ability to see and fix a graft immediately offers a reliable path to better patient health. This approach does not replace the surgeon's skill but enhances it, turning a complex, high-stakes procedure into one where the outcome can be verified with certainty before the patient ever wakes up.